Skip to main content

AlphaCentric Advisors LLC

SEC CIK
0001913464
Latest filing
Jul 24, 2026

CLDX holding history

Celldex Therapeutics, Inc. in every 13F filed by AlphaCentric Advisors LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

CLDX overviewAll 13F holders of CLDXFull Q2 2026 holdings

Shares (Q2 2026)
12,784
Value
$475.7K
% of portfolio
0.4%
Quarters held
14
Since Q1 2021
Holdings of CLDX by AlphaCentric Advisors LLC, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 202612,784$475.7K0.4%+170+1.3%AddedHolders
Q1 202612,614$400.1K0.4%+12,614NewHolders
Q4 20240$00.0%−30,000−100.0%Sold outHolders
Q3 202430,000$1.02M0.8%−17,500−36.8%ReducedHolders
Q2 202447,500$1.76M1.3%+9,000+23.4%AddedHolders
Q1 202438,500$1.62M1.0%+38,500NewHolders
Q4 20230$00.0%−15,000−100.0%Sold outHolders
Q3 202315,000$412.8K0.2%00.0%UnchangedHolders
Q2 202315,000$508.9K0.3%00.0%UnchangedHolders
Q1 202315,000$539.7K0.4%00.0%UnchangedHolders
Q4 202215,000$668.5K0.7%−2,000−11.8%ReducedHolders
Q3 202217,000$478.0K0.5%–No prior filingHolders
Q1 2022––––Not filedHolders
Q4 202117,000$657.0K0.2%00.0%UnchangedHolders
Q3 202117,000$918.0K0.2%−8,000−32.0%ReducedHolders
Q2 202125,000$836.0K0.2%00.0%UnchangedHolders
Q1 202125,000$515.0K0.2%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.